z-logo
open-access-imgOpen Access
Biased signaling by endogenous opioid peptides
Author(s) -
Ivone Gomes,
Salvador Sierra,
Lindsay M. Lueptow,
Achla Gupta,
Shawn Gouty,
Elyssa B. Margolis,
Brian M. Cox,
Lakshmi A. Devi
Publication year - 2020
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2000712117
Subject(s) - opioid peptide , dynorphin , receptor , opioid , proenkephalin , endogenous opioid , opioid receptor , pharmacology , chemistry , functional selectivity , endorphins , neuroscience , agonist , biology , biochemistry
Significance There are >20 different endogenous opioid peptides derived from the three precursors proopiomelanocortin, proenkephalin, and prodynorphin; a long-standing question is the biological utility of having this variety of peptides. We addressed this question by systematically evaluating ligand binding and signaling properties of the peptides at each of the three opioid receptor types. Contrary to the prevailing notion, we show that all of the peptides bind and activate the three opioid receptors and that shorter β-endorphin peptides exhibit agonistic activity. Finally, we demonstrate that some endogenous peptides favor particular signaling pathways at the three receptors leading to biased signaling. These findings highlight the complexity of signaling where multiple opioid receptors are expressed and/or many opioid peptides are released.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom